<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31314657</PMID><DateCompleted><Year>2020</Year><Month>02</Month><Day>18</Day></DateCompleted><DateRevised><Year>2020</Year><Month>02</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>10</Issue><PubDate><Year>2019</Year></PubDate></JournalIssue><Title>Human vaccines &amp; immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>Does structurally-mature dengue virion matter in vaccine preparation in post-Dengvaxia era?</ArticleTitle><Pagination><StartPage>2328</StartPage><EndPage>2336</EndPage><MedlinePgn>2328-2336</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2019.1643676</ELocationID><Abstract><AbstractText>The unexpectedly low vaccine efficacy of Dengvaxia&#xae;, developed by Sanofi Pasteur, and a higher risk of severe diseases after vaccination among dengue-naive children or children younger than 6&#xa0;years old, have cast skepticism about the safety of dengue vaccination resulting in the suspension of school-based immunization programs in the Philippines. The absence of immune correlates of protection from dengue virus (DENV) infection hampers the development of other potential DENV vaccines. While tetravalent live-attenuated tetravalent vaccines (LATVs), which mimic natural infection by inducing both cellular and humoral immune responses, are still currently favored, developing a vaccine that provides a balanced immunity to all four DENV serotypes remains a challenge. With the recently advanced understanding of virion structure and B cell immune responses from naturally infected DENV patients, two points of view in developing a next-generation dengue vaccine emerged: one is to induce potent, type-specific neutralizing antibodies (NtAbs) recognizing quaternary structure-dependent epitopes by having four components of vaccine strains replicate equivalently; the other is to induce protective and broadly NtAbs against the four serotypes of DENV with a universal vaccine. This article reviews the studies related to these issues and the current knowledge gap that needs to be filled in.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Galula</LastName><ForeName>Jedhan Ucat</ForeName><Initials>JU</Initials><AffiliationInfo><Affiliation>Graduate Institute of Microbiology and Public Health, College of Veterinary Medicine, National Chung Hsing University , Taichung , Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salem</LastName><ForeName>Gielenny M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Graduate Institute of Microbiology and Public Health, College of Veterinary Medicine, National Chung Hsing University , Taichung , Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Gwong-Jen J</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, US Department of Health and Human Services , Fort Collins , CO , USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chao</LastName><ForeName>Day-Yu</ForeName><Initials>DY</Initials><AffiliationInfo><Affiliation>Graduate Institute of Microbiology and Public Health, College of Veterinary Medicine, National Chung Hsing University , Taichung , Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>08</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053059">Dengue Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014613">Vaccines, Attenuated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058425">Vaccines, Virus-Like Particle</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003715" MajorTopicYN="N">Dengue</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053059" MajorTopicYN="N">Dengue Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003716" MajorTopicYN="N">Dengue Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065288" MajorTopicYN="N">Serogroup</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014613" MajorTopicYN="N">Vaccines, Attenuated</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058425" MajorTopicYN="N">Vaccines, Virus-Like Particle</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014771" MajorTopicYN="N">Virion</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Dengue virus</Keyword><Keyword MajorTopicYN="N">broadly neutralizing antibody</Keyword><Keyword MajorTopicYN="N">dengue</Keyword><Keyword MajorTopicYN="N">maturity</Keyword><Keyword MajorTopicYN="N">virus-like particles</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>7</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>2</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>7</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31314657</ArticleId><ArticleId IdType="pmc">PMC6816432</ArticleId><ArticleId IdType="doi">10.1080/21645515.2019.1643676</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chambers TJ, Hahn CS, Galler R, Rice CM.. Flavivirus genome: organization, expression and replication. Annu Rev Microbiol. 1990;44:649&#x2013;88. doi:10.1146/annurev.mi.44.100190.003245.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.mi.44.100190.003245</ArticleId><ArticleId IdType="pubmed">2174669</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O, et al. The global distribution and burden of dengue. Nature. 2013;496:504&#x2013;07. doi:10.1038/nature12060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature12060</ArticleId><ArticleId IdType="pmc">PMC3651993</ArticleId><ArticleId IdType="pubmed">23563266</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyle J, Harris E. Global spread and persistence of dengue. Annu Rev Microbiol. 2008;62:71&#x2013;92. doi:10.1146/annurev.micro.62.081307.163005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.micro.62.081307.163005</ArticleId><ArticleId IdType="pubmed">18429680</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadinegoro S, Arredondo-Garc&#xed;a JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, Muhammad Ismail HIH, Reynales H, Limkittikul K, Rivera-Medina DM, et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med. 2015;373:1195&#x2013;206. doi:10.1056/NEJMoa1506223.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1506223</ArticleId><ArticleId IdType="pubmed">26214039</ArticleId></ArticleIdList></Reference><Reference><Citation>Capeding M, Tran N, Hadinegoro S, Ismail H, Chotpitayasunondh T, Chua M, Luong C, Rusmil K, Wirawan D, Nallusamy R, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. 2014. doi:10.1016/S0140-6736(14)61060-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(14)61060-6</ArticleId><ArticleId IdType="pubmed">25018116</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Barraquer I, Mier-Y-Teran-Romero L, Ferguson N, Burke D, Cummings D. Differential efficacy of dengue vaccine by immune status. Lancet. 2015;385:1726. doi:10.1016/S0140-6736(15)60889-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(15)60889-3</ArticleId><ArticleId IdType="pubmed">25943936</ArticleId></ArticleIdList></Reference><Reference><Citation>Halstead S. Dengvaxia sensitizes seronegatives to vaccine enhanced disease regardless of age. Vaccine. 2017;35:6355&#x2013;58. doi:10.1016/j.vaccine.2017.09.089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2017.09.089</ArticleId><ArticleId IdType="pubmed">29029938</ArticleId></ArticleIdList></Reference><Reference><Citation>Sridhar S, Luedtke A, Langevin E, Zhu M, Bonaparte M, Machabert T, Savarino S, Zambrano B, Moureau A, Khromava A, et al. Effect of dengue serostatus on dengue vaccine safety and efficacy. N Engl J Med. 2018;379:327&#x2013;40. doi:10.1056/NEJMoa1800820.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1800820</ArticleId><ArticleId IdType="pubmed">29897841</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization Dengue vaccine: WHO position paper, July 2016 - recommendations. Vaccine. 2017;35:1200&#x2013;01. doi:10.1016/j.vaccine.2016.10.070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2016.10.070</ArticleId><ArticleId IdType="pubmed">28185744</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilder-Smith A, Hombach J, Ferguson N, Selgelid M, O&#x2019;Brien K, Vannice K, Barrett A, Ferdinand E, Flasche S, Guzman M, et al. Deliberations of the strategic advisory group of experts on immunization on the use of CYD-TDV dengue vaccine. Lancet Infect Dis. 2019;19:e31&#x2013;e38. doi:10.1016/S1473-3099(18)30494-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(18)30494-8</ArticleId><ArticleId IdType="pubmed">30195995</ArticleId></ArticleIdList></Reference><Reference><Citation>Pang T, Gubler D, Goh D, Ismail Z, Asia Dengue Vaccine Advocacy Group . Dengue vaccination: a more balanced approach is needed. Lancet. 2018;391:654. doi:10.1016/S0140-6736(18)30245-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)30245-9</ArticleId><ArticleId IdType="pubmed">29617262</ArticleId></ArticleIdList></Reference><Reference><Citation>Durbin AP, Gubler DJ. What is the prospect of a safe and effective dengue vaccine for travelers? J Travel Med. 2019. doi:10.1093/jtm/tay153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jtm/tay153</ArticleId><ArticleId IdType="pubmed">30657935</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitehead S, Subbarao K. Which dengue vaccine approach is the most promising, and should we be concerned about enhanced disease after vaccination? The risks of incomplete immunity to dengue virus revealed by vaccination. Cold Spring Harb Perspect Biol. 2018;10:a028811. doi:10.1101/cshperspect.a028811.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a028811</ArticleId><ArticleId IdType="pmc">PMC5983189</ArticleId><ArticleId IdType="pubmed">28716894</ArticleId></ArticleIdList></Reference><Reference><Citation>Guy B, Lang J, Saville M, Jackson N. Vaccination against dengue: challenges and current developments. Annu Rev Med. 2016;67:387&#x2013;404. doi:10.1146/annurev-med-091014-090848.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-med-091014-090848</ArticleId><ArticleId IdType="pubmed">26515983</ArticleId></ArticleIdList></Reference><Reference><Citation>Guy B. Which dengue vaccine approach is the most promising, and should we be concerned about enhanced disease after vaccination? Questions raised by the development and implementation of dengue vaccines: example of the Sanofi Pasteur tetravalent dengue vaccine. Cold Spring Harb Perspect Biol. 2018;10:a029462. doi:10.1101/cshperspect.a029462.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a029462</ArticleId><ArticleId IdType="pmc">PMC5983191</ArticleId><ArticleId IdType="pubmed">28716892</ArticleId></ArticleIdList></Reference><Reference><Citation>de Silva A, Harris E. Which dengue vaccine approach is the most promising, and should we be concerned about enhanced disease after vaccination? The path to a dengue vaccine: learning from human natural dengue infection studies and vaccine trials. Cold Spring Harb Perspect Biol. 2018;10:a029371. doi:10.1101/cshperspect.a029371.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a029371</ArticleId><ArticleId IdType="pmc">PMC5983190</ArticleId><ArticleId IdType="pubmed">28716891</ArticleId></ArticleIdList></Reference><Reference><Citation>Screaton G, Mongkolsapaya J. Which dengue vaccine approach is the most promising, and should we be concerned about enhanced disease after vaccination? The challenges of a dengue vaccine. Cold Spring Harb Perspect Biol. 2018;10:a029520. doi:10.1101/cshperspect.a029520.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a029520</ArticleId><ArticleId IdType="pmc">PMC5983192</ArticleId><ArticleId IdType="pubmed">28716884</ArticleId></ArticleIdList></Reference><Reference><Citation>Guy B, Jackson N. Dengue vaccine: hypotheses to understand CYD-TDV-induced protection. Nat Rev Microbiol. 2016;14:45&#x2013;54. doi:10.1038/nrmicro.2015.2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrmicro.2015.2</ArticleId><ArticleId IdType="pubmed">26639777</ArticleId></ArticleIdList></Reference><Reference><Citation>Plotkin S. Dengue vaccine, A double-edged sword. J Pediatric Infect Dis Soc. 2019. January 18. doi: 10.1093/jpids/piy140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jpids/piy140</ArticleId><ArticleId IdType="pubmed">30657941</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilder-Smith A. Four-year safety follow-up of the tetravalent dengue vaccine CYD-TDV. Clin Microbiol Infect. 2018;24:680&#x2013;81. doi:10.1016/j.cmi.2018.03.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2018.03.024</ArticleId><ArticleId IdType="pubmed">29581052</ArticleId></ArticleIdList></Reference><Reference><Citation>Vannice K, Wilder-Smith A, Barrett ADT, Carrijo K, Cavaleri M, de Silva A, Durbin AP, Endy T, Harris E, Innis BL, et al. Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines. Vaccine. 2018;36:3411&#x2013;17. doi:10.1016/j.vaccine.2018.02.062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2018.02.062</ArticleId><ArticleId IdType="pmc">PMC6010224</ArticleId><ArticleId IdType="pubmed">29525283</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson K, Endy T, Thomas S. The dynamic role of dengue cross-reactive immunity: changing the approach to defining vaccine safety and efficacy. Lancet Infect Dis. 2018;18:e333&#x2013;e338. doi:10.1016/S1473-3099(18)30126-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(18)30126-9</ArticleId><ArticleId IdType="pubmed">29784457</ArticleId></ArticleIdList></Reference><Reference><Citation>Tripathi N, Shrivastava A. Recent developments in recombinant protein-based dengue vaccines. Front Immunol. 2018;9:1919. doi:10.3389/fimmu.2018.01919.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.01919</ArticleId><ArticleId IdType="pmc">PMC6115509</ArticleId><ArticleId IdType="pubmed">30190720</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilder-Smith A, Ooi E, Horstick O, Wills B. Dengue. Lancet. 2019;393:350&#x2013;63. doi:10.1016/S0140-6736(18)32560-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)32560-1</ArticleId><ArticleId IdType="pubmed">30696575</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization Dengue: guidelines for diagnosis, treatment, prevention and control. New ed. Geneva, Switzerland: WHO Press; Chp 4; 2009. p. 91&#x2013;106.</Citation></Reference><Reference><Citation>Torresi J, Ebert G, Pellegrini M. Vaccines licensed and in clinical trials for the prevention of dengue. Hum Vaccin Immunother. 2017;13:1059&#x2013;72. doi:10.1080/21645515.2016.1261770.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2016.1261770</ArticleId><ArticleId IdType="pmc">PMC5443395</ArticleId><ArticleId IdType="pubmed">28281864</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitehead S. Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD&#x2122; vaccine? Expert Rev Vaccines. 2016;15:509&#x2013;17. doi:10.1586/14760584.2016.1115727.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14760584.2016.1115727</ArticleId><ArticleId IdType="pmc">PMC4956407</ArticleId><ArticleId IdType="pubmed">26559731</ArticleId></ArticleIdList></Reference><Reference><Citation>SB H. Which dengue vaccine approach is the most promising, and should we be concerned about enhanced disease after vaccination? There is only one true winner. Cold Spring Harb Perspect Biol. 2018;10:a030700. doi:10.1101/cshperspect.a030700.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a030700</ArticleId><ArticleId IdType="pmc">PMC5983193</ArticleId><ArticleId IdType="pubmed">28716893</ArticleId></ArticleIdList></Reference><Reference><Citation>Dowd K, Pierson T. The many faces of a dynamic virion: implications of viral breathing on flavivirus biology and immunogenicity. Annu Rev Virol. 2018;5:185&#x2013;207. doi:10.1146/annurev-virology-092917-043300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-virology-092917-043300</ArticleId><ArticleId IdType="pubmed">30265634</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, Lok S-M, Yu I-M, Zhang Y, Kuhn RJ, Chen J, Rossmann MG. The flavivirus precursor membrane-envelope protein complex: structure and maturation. Science. 2008;319:1830&#x2013;34. doi:10.1126/science.1153263.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1153263</ArticleId><ArticleId IdType="pubmed">18369147</ArticleId></ArticleIdList></Reference><Reference><Citation>Kostyuchenko V, Zhang Q, Tan J, Ng T, Lok S. Immature and mature dengue serotype 1 virus structures provide insight into the maturation process. J Virol. 2013;87:7700&#x2013;07. doi:10.1128/JVI.00197-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00197-13</ArticleId><ArticleId IdType="pmc">PMC3700294</ArticleId><ArticleId IdType="pubmed">23637416</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen W, Galula JU, Liu JH, Liao MY, Huang CH, Wang YC, Wu HC, Liang JJ, Lin YL, Whitney MT, et al. Epitope resurfacing on dengue virus-like particle vaccine preparation to induce broad neutralizing antibody. Elife. 2018;7:e38970. doi: 10.7554/eLife.38970.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.38970</ArticleId><ArticleId IdType="pmc">PMC6234032</ArticleId><ArticleId IdType="pubmed">30334522</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian S, Huajun W, Wu J. Computational prediction of furin cleavage sites by a hybrid method and understanding mechanism underlying diseases. Sci Rep. 2012;2:261. doi: 10.1038/srep00261.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep00261</ArticleId><ArticleId IdType="pmc">PMC3281273</ArticleId><ArticleId IdType="pubmed">22355773</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierson T, Diamond M. Degrees of maturity: the complex structure and biology of flaviviruses. Curr Opin Virol. 2012;2:168&#x2013;75. doi:10.1016/j.coviro.2012.02.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coviro.2012.02.011</ArticleId><ArticleId IdType="pmc">PMC3715965</ArticleId><ArticleId IdType="pubmed">22445964</ArticleId></ArticleIdList></Reference><Reference><Citation>Junjhon J, Edwards TJ, Utaipat U, Bowman VD, Holdaway HA, Zhang W, Keelapang P, Puttikhunt C, Perera R, Chipman PR, et al. Influence of pr-M cleavage on the heterogeneity of extracellular dengue virus particles. J Virol. 2010;84:8353&#x2013;58. doi:10.1128/JVI.00696-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00696-10</ArticleId><ArticleId IdType="pmc">PMC2916513</ArticleId><ArticleId IdType="pubmed">20519400</ArticleId></ArticleIdList></Reference><Reference><Citation>Raut R, Corbett KS, Tennekoon RN, Premawansa S, Wijewickrama A, Premawansa G, Mieczkowski P, R&#xfc;ckert C, Ebel GD, De Silva AD, et al. Dengue type 1 viruses circulating in humans are highly infectious and poorly neutralized by human antibodies. Proc Natl Acad Sci U S A. 2019;116:227&#x2013;32. doi:10.1073/pnas.1812055115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1812055115</ArticleId><ArticleId IdType="pmc">PMC6320508</ArticleId><ArticleId IdType="pubmed">30518559</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, Limpitikul W, Puttikhunt C, Edwards C, Duangchinda T, Supasa S, et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science. 2010;328:745&#x2013;48. doi:10.1126/science.1185181.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1185181</ArticleId><ArticleId IdType="pmc">PMC3837288</ArticleId><ArticleId IdType="pubmed">20448183</ArticleId></ArticleIdList></Reference><Reference><Citation>Katzelnick L, Fonville JM, Gromowski GD, Bustos Arriaga J, Green A, James SL, Lau L, Montoya M, Wang C, VanBlargan LA, et al. Dengue viruses cluster antigenically but not as discrete serotypes. Science. 2015;349:1338&#x2013;43. doi:10.1126/science.aac5017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aac5017</ArticleId><ArticleId IdType="pmc">PMC4876809</ArticleId><ArticleId IdType="pubmed">26383952</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn RJ, Zhang W, Rossmann MG, Pletnev SV, Corver J, Lenches E, Jones CT, Mukhopadhyay S, Chipman PR, Strauss EG, et al. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell. 2002;108:717&#x2013;25. doi:10.1016/s0092-8674(02)00660-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0092-8674(02)00660-8</ArticleId><ArticleId IdType="pmc">PMC4152842</ArticleId><ArticleId IdType="pubmed">11893341</ArticleId></ArticleIdList></Reference><Reference><Citation>Fibriansah G, Ng T-S, Kostyuchenko VA, Lee J, Lee S, Wang J, Lok S-M. Structural changes in dengue virus when exposed to a temperature of 37&#xb0;C. J Virol. 2013;87:7585&#x2013;92. doi:10.1128/JVI.00757-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00757-13</ArticleId><ArticleId IdType="pmc">PMC3700303</ArticleId><ArticleId IdType="pubmed">23637405</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn R, Dowd K, Beth Post C, Pierson T. Shake, rattle, and roll: impact of the dynamics of flavivirus particles on their interactions with the host. Virology. 2015;479&#x2013;480:508&#x2013;17. doi:10.1016/j.virol.2015.03.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2015.03.025</ArticleId><ArticleId IdType="pmc">PMC4900690</ArticleId><ArticleId IdType="pubmed">25835729</ArticleId></ArticleIdList></Reference><Reference><Citation>Dowd K, Mukherjee S, Kuhn R, Pierson T. Combined effects of the structural heterogeneity and dynamics of flaviviruses on antibody recognition. J Virol. 2014;88:11726&#x2013;37. doi:10.1128/JVI.01140-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01140-14</ArticleId><ArticleId IdType="pmc">PMC4178732</ArticleId><ArticleId IdType="pubmed">25078693</ArticleId></ArticleIdList></Reference><Reference><Citation>Modis Y, Ogata S, Clements D, Harrison S. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci. 2003;100:6986&#x2013;91. doi:10.1073/pnas.0832193100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0832193100</ArticleId><ArticleId IdType="pmc">PMC165817</ArticleId><ArticleId IdType="pubmed">12759475</ArticleId></ArticleIdList></Reference><Reference><Citation>Roehrig JT. Antigenic structure of flavivirus proteins. Adv Virus Res. 2003;59:141&#x2013;75. doi:10.1016/s0065-3527(03)59005-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0065-3527(03)59005-4</ArticleId><ArticleId IdType="pubmed">14696329</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierson T, Fremont D, Kuhn R, Diamond M. Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development. Cell Host Microbe. 2008;4:229&#x2013;38. doi:10.1016/j.chom.2008.08.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2008.08.004</ArticleId><ArticleId IdType="pmc">PMC2678546</ArticleId><ArticleId IdType="pubmed">18779049</ArticleId></ArticleIdList></Reference><Reference><Citation>Dowd K, Pierson T. Antibody-mediated neutralization of flaviviruses: a reductionist view. Virology. 2011;411:306&#x2013;15. doi:10.1016/j.virol.2010.12.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2010.12.020</ArticleId><ArticleId IdType="pmc">PMC3100196</ArticleId><ArticleId IdType="pubmed">21255816</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierson T, Diamond M. A game of numbers: the stoichiometry of antibody-mediated neutralization of flavivirus infection. Prog Mol Biol Transl Sci. 2015;129:141&#x2013;66. doi:10.1016/bs.pmbts.2014.10.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.pmbts.2014.10.005</ArticleId><ArticleId IdType="pmc">PMC4910618</ArticleId><ArticleId IdType="pubmed">25595803</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierson TC, Xu Q, Nelson S, Oliphant T, Nybakken GE, Fremont DH, Diamond MS. The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe. 2007;1:135&#x2013;45. doi:10.1016/j.chom.2007.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2007.03.002</ArticleId><ArticleId IdType="pmc">PMC2656919</ArticleId><ArticleId IdType="pubmed">18005691</ArticleId></ArticleIdList></Reference><Reference><Citation>Katzelnick L, Gresh L, Halloran ME, Mercado JC, Kuan G, Gordon A, Balmaseda A, Harris E. Antibody-dependent enhancement of severe dengue disease in humans. Science. 2017;358:929&#x2013;32. doi:10.1126/science.aan6836.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aan6836</ArticleId><ArticleId IdType="pmc">PMC5858873</ArticleId><ArticleId IdType="pubmed">29097492</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson S, Jost CA, Xu Q, Ess J, Martin JE, Oliphant T, Whitehead SS, Durbin AP, Graham BS, Diamond MS, et al. Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization. PLoS Pathog. 2008;4:e1000060. doi:10.1371/journal.ppat.1000060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1000060</ArticleId><ArticleId IdType="pmc">PMC2330159</ArticleId><ArticleId IdType="pubmed">18464894</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejnirattisai W, Wongwiwat W, Supasa S, Zhang X, Dai X, Rouvinski A, Jumnainsong A, Edwards C, Quyen NTH, Duangchinda T, et al. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat Immunol. 2015;16:170&#x2013;77. doi:10.1038/ni.3058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.3058</ArticleId><ArticleId IdType="pmc">PMC4445969</ArticleId><ArticleId IdType="pubmed">25501631</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherrier MV, Kaufmann B, Nybakken GE, Lok S-M, Warren JT, Chen BR, Nelson CA, Kostyuchenko VA, Holdaway HA, Chipman PR, et al. Structural basis for the preferential recognition of immature flaviviruses by a fusion-loop antibody. Embo J. 2009;28:3269&#x2013;76. doi:10.1038/emboj.2009.245.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2009.245</ArticleId><ArticleId IdType="pmc">PMC2771083</ArticleId><ArticleId IdType="pubmed">19713934</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrone S, Lok S. Structural perspectives of antibody-dependent enhancement of infection of dengue virus. Curr Opin Virol. 2019;36:1&#x2013;8. doi:10.1016/j.coviro.2019.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coviro.2019.02.002</ArticleId><ArticleId IdType="pubmed">30844538</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodenhuis-Zybert I, Da Silva Voorham J, Torres S, van de Pol D, Smit J. Antibodies against immature virions are not a discriminating factor for dengue disease severity. PLoS Negl Trop Dis. 2015;9:e0003564. doi:10.1371/journal.pntd.0003564.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0003564</ArticleId><ArticleId IdType="pmc">PMC4356584</ArticleId><ArticleId IdType="pubmed">25760350</ArticleId></ArticleIdList></Reference><Reference><Citation>Cyster JG, Allen CDC. B cell responses: cell interaction dynamics and decisions. Cell. 2019;177:524&#x2013;40. doi:10.1016/j.cell.2019.03.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2019.03.016</ArticleId><ArticleId IdType="pmc">PMC6538279</ArticleId><ArticleId IdType="pubmed">31002794</ArticleId></ArticleIdList></Reference><Reference><Citation>de Alwis R, Smith SA, Olivarez NP, Messer WB, Huynh JP, Wahala WMPB, White LJ, Diamond MS, Baric RS, Crowe JE, et al. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci U S A. 2012;109:7439&#x2013;44. doi:10.1073/pnas.1200566109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1200566109</ArticleId><ArticleId IdType="pmc">PMC3358852</ArticleId><ArticleId IdType="pubmed">22499787</ArticleId></ArticleIdList></Reference><Reference><Citation>de Alwis R, Williams KL, Schmid MA, Lai C-Y, Patel B, Smith SA, Crowe JE, Wang W-K, Harris E, de Silva AM, et al. Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera. PLoS Pathog. 2014;10:e1004386. doi:10.1371/journal.ppat.1004386.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1004386</ArticleId><ArticleId IdType="pmc">PMC4183589</ArticleId><ArticleId IdType="pubmed">25275316</ArticleId></ArticleIdList></Reference><Reference><Citation>Beltramello M, Williams KL, Simmons CP, Macagno A, Simonelli L, Quyen NTH, Sukupolvi-Petty S, Navarro-Sanchez E, Young PR, de Silva AM, et al. The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe. 2010;8:271&#x2013;83. doi:10.1016/j.chom.2010.08.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2010.08.007</ArticleId><ArticleId IdType="pmc">PMC3884547</ArticleId><ArticleId IdType="pubmed">20833378</ArticleId></ArticleIdList></Reference><Reference><Citation>Wrammert J, Onlamoon N, Akondy RS, Perng GC, Polsrila K, Chandele A, Kwissa M, Pulendran B, Wilson PC, Wittawatmongkol O, et al. Rapid and massive virus-specific plasmablast responses during acute dengue virus infection in humans. J Virol. 2012;86:2911&#x2013;18. doi:10.1128/JVI.06075-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.06075-11</ArticleId><ArticleId IdType="pmc">PMC3302324</ArticleId><ArticleId IdType="pubmed">22238318</ArticleId></ArticleIdList></Reference><Reference><Citation>Priyamvada L, Cho A, Onlamoon N, Zheng N-Y, Huang M, Kovalenkov Y, Chokephaibulkit K, Angkasekwinai N, Pattanapanyasat K, Ahmed R, et al. B cell responses during secondary dengue virus infection are dominated by highly cross-reactive, memory-derived plasmablasts. J Virol. 2016;90:5574&#x2013;85. doi:10.1128/JVI.03203-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.03203-15</ArticleId><ArticleId IdType="pmc">PMC4886779</ArticleId><ArticleId IdType="pubmed">27030262</ArticleId></ArticleIdList></Reference><Reference><Citation>Corbett K, Katzelnick L, Tissera H, Amerasinghe A, de Silva AD, de Silva AM. Preexisting neutralizing antibody responses distinguish clinically inapparent and apparent dengue virus infections in a Sri Lankan pediatric cohort. J Infect Dis. 2015;211:590&#x2013;99. doi:10.1093/infdis/jiu481.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiu481</ArticleId><ArticleId IdType="pmc">PMC4375390</ArticleId><ArticleId IdType="pubmed">25336728</ArticleId></ArticleIdList></Reference><Reference><Citation>Durbin A, Schmidt A, Elwood D, Wanionek KA, Lovchik J, Thumar B, Murphy BR, Whitehead SS. Heterotypic dengue infection with live attenuated monotypic dengue virus vaccines: implications for vaccination of populations in areas where dengue is endemic. J Infect Dis. 2011;203:327&#x2013;34. doi:10.1093/infdis/jiq059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiq059</ArticleId><ArticleId IdType="pmc">PMC3071099</ArticleId><ArticleId IdType="pubmed">21208923</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbons R, Kalanarooj S, Jarman RG, Nisalak A, Vaughn DW, Endy TP, Mammen MP, Srikiatkhachorn A. Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences. Am J Trop Med Hyg. 2007;77:910&#x2013;13. doi:10.4269/ajtmh.2007.77.910.</Citation><ArticleIdList><ArticleId IdType="doi">10.4269/ajtmh.2007.77.910</ArticleId><ArticleId IdType="pubmed">17984352</ArticleId></ArticleIdList></Reference><Reference><Citation>Olkowski S, Forshey BM, Morrison AC, Rocha C, Vilcarromero S, Halsey ES, Kochel TJ, Scott TW, Stoddard ST. Reduced risk of disease during postsecondary dengue virus infections. J Infect Dis. 2013;208:1026&#x2013;33. doi:10.1093/infdis/jit273.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jit273</ArticleId><ArticleId IdType="pmc">PMC3749012</ArticleId><ArticleId IdType="pubmed">23776195</ArticleId></ArticleIdList></Reference><Reference><Citation>Screaton G, Mongkolsapaya J, Yacoub S, Roberts C. New insights into the immunopathology and control of dengue virus infection. Nat Rev Immunol. 2015;15:745&#x2013;59. doi:10.1038/nri3916.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3916</ArticleId><ArticleId IdType="pubmed">26603900</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SA, de Alwis AR, Kose N, Harris E, Ibarra KD, Kahle KM, Pfaff JM, Xiang X, Doranz BJ, de Silva AM, et al. The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein. MBio. 2013;4:e00873&#x2013;00813. doi:10.1128/mBio.00873-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.00873-13</ArticleId><ArticleId IdType="pmc">PMC3870244</ArticleId><ArticleId IdType="pubmed">24255124</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai W, Lai C-Y, Wu Y-C, Lin H-E, Edwards C, Jumnainsong A, Kliks S, Halstead S, Mongkolsapaya J, Screaton GR, et al. High-avidity and potently neutralizing cross-reactive human monoclonal antibodies derived from secondary dengue virus infection. J Virol. 2013;87:12562&#x2013;75. doi:10.1128/JVI.00871-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00871-13</ArticleId><ArticleId IdType="pmc">PMC3838129</ArticleId><ArticleId IdType="pubmed">24027331</ArticleId></ArticleIdList></Reference><Reference><Citation>Rouvinski A, Guardado-Calvo P, Barba-Spaeth G, Duquerroy S, Vaney M-C, Kikuti CM, Navarro Sanchez ME, Dejnirattisai W, Wongwiwat W, Haouz A, et al. Recognition determinants of broadly neutralizing human antibodies against dengue viruses. Nature. 2015;520:109&#x2013;13. doi:10.1038/nature14130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14130</ArticleId><ArticleId IdType="pubmed">25581790</ArticleId></ArticleIdList></Reference><Reference><Citation>Fibriansah G, Tan JL, Smith SA, de Alwis AR, Ng T-S, Kostyuchenko VA, Ibarra KD, Wang J, Harris E, de Silva A, et al. A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface. EMBO Mol Med. 2014;6:358&#x2013;71. doi:10.1002/emmm.201303404.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/emmm.201303404</ArticleId><ArticleId IdType="pmc">PMC3958310</ArticleId><ArticleId IdType="pubmed">24421336</ArticleId></ArticleIdList></Reference><Reference><Citation>Teoh E, Kukkaro P, Teo EW, Lim APC, Tan TT, Yip A, Schul W, Aung M, Kostyuchenko VA, Leo YS, et al. The structural basis for serotype-specific neutralization of dengue virus by a human antibody. Sci Transl Med. 2012;4:139ra183. doi:10.1126/scitranslmed.3003888.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3003888</ArticleId><ArticleId IdType="pubmed">22723463</ArticleId></ArticleIdList></Reference><Reference><Citation>Fibriansah G, Tan JL, Smith SA, de Alwis R, Ng T-S, Kostyuchenko VA, Jadi RS, Kukkaro P, de Silva AM, Crowe JE, et al. A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins. Nat Commun. 2015;6. doi:10.1038/ncomms7341.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms7341</ArticleId><ArticleId IdType="pmc">PMC4346626</ArticleId><ArticleId IdType="pubmed">25698059</ArticleId></ArticleIdList></Reference><Reference><Citation>Fibriansah G, Ibarra KD, Ng T-S, Smith SA, Tan JL, Lim X-N, Ooi JSG, Kostyuchenko VA, Wang J, de Silva AM, et al. DENGUE VIRUS. Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers. Science. 2015;349:88&#x2013;91. doi:10.1126/science.aaa8651.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaa8651</ArticleId><ArticleId IdType="pmc">PMC4672004</ArticleId><ArticleId IdType="pubmed">26138979</ArticleId></ArticleIdList></Reference><Reference><Citation>Rey F, Stiasny K, Vaney M, Dellarole M, Heinz F. The bright and the dark side of human antibody responses to flaviviruses: lessons for vaccine design. EMBO Rep. 2018;19:206&#x2013;24. doi:10.15252/embr.201745302.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embr.201745302</ArticleId><ArticleId IdType="pmc">PMC5797954</ArticleId><ArticleId IdType="pubmed">29282215</ArticleId></ArticleIdList></Reference><Reference><Citation>Slon CJ, Mongkolsapaya J, Screaton G. The immune response against flaviviruses. Nat Immunol. 2018;19:1189&#x2013;98. doi:10.1038/s41590-018-0210-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-018-0210-3</ArticleId><ArticleId IdType="pubmed">30333606</ArticleId></ArticleIdList></Reference><Reference><Citation>Crill WD, Hughes HR, Trainor NB, Davis BS, Whitney MT, Chang GJJ. Sculpting humoral immunity through dengue vaccination to enhance protective immunity. Front Immunol. 2012;3:334. doi: 10.3389/fimmu.2012.00334.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2012.00334</ArticleId><ArticleId IdType="pmc">PMC3492872</ArticleId><ArticleId IdType="pubmed">23162552</ArticleId></ArticleIdList></Reference><Reference><Citation>Chao D-Y, Crill WD, Davis BS, Chang G-J-J. Can reductions in the cross-reactivity of flavivirus structural proteins lead to improved safety and immunogenicity of tetravalent dengue vaccine development? Future Virol. 2015;10:477&#x2013;80. doi:10.2217/fvl.15.13.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fvl.15.13</ArticleId></ArticleIdList></Reference><Reference><Citation>Keelapang P, Nitatpattana N, Suphatrakul A, Punyahathaikul S, Sriburi R, Pulmanausahakul R, Pichyangkul S, Malasit P, Yoksan S, Sittisombut N. Generation and preclinical evaluation of a DENV-1/2 prM+E chimeric live attenuated vaccine candidate with enhanced prM cleavage. Vaccine. 2013;31:5134&#x2013;40. doi:10.1016/j.vaccine.2013.08.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.08.027</ArticleId><ArticleId IdType="pubmed">23973247</ArticleId></ArticleIdList></Reference><Reference><Citation>Rouvinski A, Dejnirattisai W, Guardado-Calvo P, Vaney M-C, Sharma A, Duquerroy S, Supasa P, Wongwiwat W, Haouz A, Barba-Spaeth G, et al. Covalently linked dengue virus envelope glycoprotein dimers reduce exposure of the immunodominant fusion loop epitope. Nat Commun. 2017;8:15411. doi:10.1038/ncomms15411.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms15411</ArticleId><ArticleId IdType="pmc">PMC5457521</ArticleId><ArticleId IdType="pubmed">28534525</ArticleId></ArticleIdList></Reference><Reference><Citation>Henein S, Swanstrom J, Byers AM, Moser JM, Shaik SF, Bonaparte M, Jackson N, Guy B, Baric R, de Silva AM. Dissecting antibodies induced by a chimeric yellow fever-dengue, live-attenuated, tetravalent dengue vaccine (CYD-TDV) in naive and dengue-exposed individuals. J Infect Dis. 2017;215:351&#x2013;58. doi:10.1093/infdis/jiw576.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiw576</ArticleId><ArticleId IdType="pmc">PMC6392503</ArticleId><ArticleId IdType="pubmed">27932620</ArticleId></ArticleIdList></Reference><Reference><Citation>Poo J, Galan F, Forrat R, Zambrano B, Lang J, Dayan G. Live-attenuated tetravalent dengue vaccine in dengue-na&#xef;ve children, adolescents, and adults in Mexico City: randomized controlled phase 1 trial of safety and immunogenicity. Pediatr Infect Dis. 2011;30:e9&#x2013;17. doi:10.1097/INF.0b013e3181fe05af.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0b013e3181fe05af</ArticleId><ArticleId IdType="pubmed">21042231</ArticleId></ArticleIdList></Reference><Reference><Citation>Dayan G, Thakur M, Boaz M, Johnson C. Safety and immunogenicity of three tetravalent dengue vaccine formulations inhealthy adults in the USA. Vaccine. 2013;31:5047&#x2013;54. doi:10.1016/j.vaccine.2013.08.088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.08.088</ArticleId><ArticleId IdType="pubmed">24021313</ArticleId></ArticleIdList></Reference><Reference><Citation>Swanstrom J, Henein S, Plante JA, Yount BL, Widman DG, Gallichotte EN, Dean HJ, Osorio JE, Partidos CD, de Silva AM, et al. Analyzing the human serum antibody responses to a live attenuated tetravalent dengue vaccine candidate. J Infect Dis. 2018;217:1932&#x2013;41. doi:10.1093/infdis/jiy063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiy063</ArticleId><ArticleId IdType="pmc">PMC5972589</ArticleId><ArticleId IdType="pubmed">29800370</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai W-Y, Durbin A, Tsai -J-J, Hsieh S-C, Whitehead S, Wang W-K. Complexity of neutralizing antibodies against multiple dengue virus serotypes after heterotypic immunization and secondary infection revealed by in-depth analysis of cross-reactive antibodies. J Virol. 2015;89:7348&#x2013;62. doi:10.1128/JVI.00273-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00273-15</ArticleId><ArticleId IdType="pmc">PMC4473561</ArticleId><ArticleId IdType="pubmed">25972550</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen J, Shresta SS. Antigenic cross-reactivity between Zika and dengue viruses: is it time to develop a universal vaccine? Curr Opin Immunol. 2019;59:1&#x2013;8. doi:10.1016/j.coi.2019.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coi.2019.02.001</ArticleId><ArticleId IdType="pmc">PMC6745280</ArticleId><ArticleId IdType="pubmed">30884384</ArticleId></ArticleIdList></Reference><Reference><Citation>Masel J, McCracken MK, Gleeson T, Morrison B, Rutherford G, Imrie A, Jarman RG, Koren M, Pollett S. Does prior dengue virus exposure worsen clinical outcomes of Zika virus infection? A systematic review, pooled analysis and lessons learned. PLoS Negl Trop Dis. 2019;13:e0007060. doi: 10.1371/journal.pntd.0007060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0007060</ArticleId><ArticleId IdType="pmc">PMC6370234</ArticleId><ArticleId IdType="pubmed">30682026</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrade D, Harris E. Recent advances in understanding the adaptive immune response to Zika virus and the effect of previous flavivirus exposure. Virus Res. 2018;254:27&#x2013;33. doi:10.1016/j.virusres.2017.06.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2017.06.019</ArticleId><ArticleId IdType="pmc">PMC5743770</ArticleId><ArticleId IdType="pubmed">28655548</ArticleId></ArticleIdList></Reference><Reference><Citation>Priyamvada L, Hudson W, Ahmed R, Wrammert J. Humoral cross-reactivity between Zika and dengue viruses: implications for protection and pathology. Emerg Microbes Infect. 2017;6:e33. doi:10.1038/emi.2017.42.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emi.2017.42</ArticleId><ArticleId IdType="pmc">PMC5520485</ArticleId><ArticleId IdType="pubmed">28487557</ArticleId></ArticleIdList></Reference><Reference><Citation>Prompetchara E, Ketloy C, Keelapang P, Sittisombut N, Ruxrungtham K. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens. Asian Pac J Allergy Immunol. 2015;33:182&#x2013;88. doi:10.12932/AP0508.33.3.2015.</Citation><ArticleIdList><ArticleId IdType="doi">10.12932/AP0508.33.3.2015</ArticleId><ArticleId IdType="pubmed">26342114</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito Y, Moi ML, Takeshita N, Lim CK, Shiba H, Hosono K, Saijo M, Kurane I, Takasaki T. Japanese encephalitis vaccine-facilitated dengue virus infection-enhancement antibody in adults. BMC Infect Dis. 2016;16:578. doi:10.1186/s12879-016-1873-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-016-1873-8</ArticleId><ArticleId IdType="pmc">PMC5070094</ArticleId><ArticleId IdType="pubmed">27756212</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitehead S, Durbin AP, Pierce KK, Elwood D, McElvany BD, Fraser EA, Carmolli MP, Tibery CM, Hynes NA, Jo M, et al. In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination. PLoS Negl Trop Dis. 2017;11:e0005584. doi:10.1371/journal.pntd.0005584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0005584</ArticleId><ArticleId IdType="pmc">PMC5436874</ArticleId><ArticleId IdType="pubmed">28481883</ArticleId></ArticleIdList></Reference><Reference><Citation>Duangchinda T, Dejnirattisai W, Vasanawathana S, Limpitikul W, Tangthawornchaikul N, Malasit P, Mongkolsapaya J, Screaton G. Immunodominant T-cell responses to dengue virus NS3 are associated with DHF. Proc Natl Acad Sci U S A. 2010;107:16922&#x2013;27. doi:10.1073/pnas.1010867107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1010867107</ArticleId><ArticleId IdType="pmc">PMC2947904</ArticleId><ArticleId IdType="pubmed">20837518</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivino L, Kumaran EAP, Jovanovic V, Nadua K, Teo EW, Pang SW, Teo GH, Gan VCH, Lye DC, Leo YS, et al. Differential targeting of viral components by CD4+ versus CD8+ T lymphocytes in dengue virus infection. J Virol. 2013;87:2693&#x2013;706. doi:10.1128/JVI.02675-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02675-12</ArticleId><ArticleId IdType="pmc">PMC3571409</ArticleId><ArticleId IdType="pubmed">23255803</ArticleId></ArticleIdList></Reference><Reference><Citation>Grifoni A, Angelo MA, Lopez B, O&#x2019;Rourke PH, Sidney J, Cerpas C, Balmaseda A, Silveira CGT, Maestri A, Costa PR, et al. Global assessment of dengue virus-specific CD4+ T cell responses in dengue-endemic areas. Front Immunol. 2017;8:1309. doi:10.3389/fimmu.2017.01309.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01309</ArticleId><ArticleId IdType="pmc">PMC5646259</ArticleId><ArticleId IdType="pubmed">29081779</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivino L. Understanding the human T cell response to dengue virus. Adv Exp Med Biol. 2018;1062:241&#x2013;50. doi:10.1007/978-981-10-8727-1_17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-981-10-8727-1_17</ArticleId><ArticleId IdType="pubmed">29845537</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivino L, Lim M. CD4+ and CD8+ T-cell immunity to Dengue - lessons for the study of Zika virus. Immunology. 2017;150:146&#x2013;54. doi:10.1111/imm.12681.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imm.12681</ArticleId><ArticleId IdType="pmc">PMC5214511</ArticleId><ArticleId IdType="pubmed">27763656</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothman A. Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat Rev Immunol. 2011;11:532&#x2013;43. doi:10.1038/nri3014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3014</ArticleId><ArticleId IdType="pubmed">21760609</ArticleId></ArticleIdList></Reference><Reference><Citation>Slifka M, Amanna I. Dengue serostatus and dengue vaccine safety and efficacy. N Engl J Med. 2018;379:1968. doi:10.1056/NEJMc1811986.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc1811986</ArticleId><ArticleId IdType="pubmed">30439281</ArticleId></ArticleIdList></Reference><Reference><Citation>Dayan G, Gal&#xe1;n-Herrera J-F, Forrat R, Zambrano B, Bouckenooghe A, Harenberg A, Guy B, Lang J. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-na&#xef;ve adults in Mexico. Hum Vaccin Immunother. 2014;10:2853&#x2013;63. doi:10.4161/21645515.2014.972131.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/21645515.2014.972131</ArticleId><ArticleId IdType="pmc">PMC5443102</ArticleId><ArticleId IdType="pubmed">25483647</ArticleId></ArticleIdList></Reference><Reference><Citation>Harenberg A, Begue S, Mamessier A, Gimenez-Fourage S, Ching Seah C, Wei Liang A, Li Ng J, Yun Toh X, Archuleta S, Wilder-Smith A, et al. Persistence of Th1/Tc1 responses one year after tetravalent dengue vaccination in adults and adolescents in Singapore. Hum Vaccin Immunother. 2013;9:2317&#x2013;25. doi:10.4161/hv.25562.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.25562</ArticleId><ArticleId IdType="pmc">PMC3981840</ArticleId><ArticleId IdType="pubmed">23839107</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu H, George S, Stinchcomb D, Osorio J, Partidos C. CD8+ T-cell responses in flavivirus-naive individuals following immunization with a live-attenuated tetravalent dengue vaccine candidate. J Infect Dis. 2015;212:1618&#x2013;28. doi:10.1093/infdis/jiv258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiv258</ArticleId><ArticleId IdType="pmc">PMC4621245</ArticleId><ArticleId IdType="pubmed">25943203</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirkpatrick B, Whitehead SS, Pierce KK, Tibery CM, Grier PL, Hynes NA, Larsson CJ, Sabundayo BP, Talaat KR, Janiak A, et al. The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model. Sci Transl Med. 2016;8:330ra336. doi:10.1126/scitranslmed.aaf1517.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aaf1517</ArticleId><ArticleId IdType="pubmed">27089205</ArticleId></ArticleIdList></Reference><Reference><Citation>Angelo M, Grifoni A, O&#x2019;Rourke PH, Sidney J, Paul S, Peters B, de Silva AD, Phillips E, Mallal S, Diehl SA, et al. Human CD4+ T cell responses to an attenuated tetravalent dengue vaccine parallel those induced by natural infection in magnitude, HLA restriction, and antigen specificity. J Virol. 2017;91:e02147&#x2013;02116. doi:10.1128/JVI.02147-16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02147-16</ArticleId><ArticleId IdType="pmc">PMC5309943</ArticleId><ArticleId IdType="pubmed">27974563</ArticleId></ArticleIdList></Reference><Reference><Citation>Katzelnick L, Coloma J, Harris E. Dengue: knowledge gaps, unmet needs, and research priorities. Lancet Infect Dis. 2017;17:e88&#x2013;e100. doi:10.1016/S1473-3099(16)30473-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(16)30473-X</ArticleId><ArticleId IdType="pmc">PMC5967882</ArticleId><ArticleId IdType="pubmed">28185868</ArticleId></ArticleIdList></Reference><Reference><Citation>St John A, Rathore A. Adaptive immune responses to primary and secondary dengue virus infections. Nat Rev Immunol. 2019. January 24. doi:10.1038/s41577-019-0123-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-019-0123-x</ArticleId><ArticleId IdType="pubmed">30679808</ArticleId></ArticleIdList></Reference><Reference><Citation>Katzelnick L, Harris E. Participants in the summit on dengue immune correlates of protection. Immune correlates of protection for dengue: state of the art and research agenda. Vaccine. 2017;35:4659&#x2013;69. doi:10.1016/j.vaccine.2017.07.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2017.07.045</ArticleId><ArticleId IdType="pmc">PMC5924688</ArticleId><ArticleId IdType="pubmed">28757058</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell P, Halstead S. Challenges to the design of clinical trials for live-attenuated tetravalent dengue vaccines. PLoS Negl Trop Dis. 2016;10:e0004854. doi:10.1371/journal.pntd.0004854.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0004854</ArticleId><ArticleId IdType="pmc">PMC4981333</ArticleId><ArticleId IdType="pubmed">27513928</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishikawa T, Yamanaka A, Konishi E. A review of successful flavivirus vaccines and the problems with those flaviviruses for which vaccines are not yet available. Vaccine. 2014;32:1326&#x2013;37. doi:10.1016/j.vaccine.2014.01.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2014.01.040</ArticleId><ArticleId IdType="pubmed">24486372</ArticleId></ArticleIdList></Reference><Reference><Citation>Plotkin S. Correlates of protection induced by vaccination. Clin Vaccine Immunol. 2010;17:1055&#x2013;65. doi:10.1128/CVI.00131-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.00131-10</ArticleId><ArticleId IdType="pmc">PMC2897268</ArticleId><ArticleId IdType="pubmed">20463105</ArticleId></ArticleIdList></Reference><Reference><Citation>Koff W, Burton DR, Johnson PR, Walker BD, King CR, Nabel GJ, Ahmed R, Bhan MK, Plotkin SA. Accelerating next-generation vaccine development for global disease prevention. Science. 2013;340:1232910. doi:10.1126/science.1232910.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1232910</ArticleId><ArticleId IdType="pmc">PMC4026248</ArticleId><ArticleId IdType="pubmed">23723240</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai W-Y, Chen H-L, Tsai -J-J, Dejnirattisai W, Jumnainsong A, Mongkolsapaya J, Screaton G, Crowe JE, Wang W-K. Potent neutralizing human monoclonal antibodies preferentially target mature dengue virus particles: implication for novel strategy for dengue vaccine. J Virol. 2018;92:e00556&#x2013;00518. doi:10.1128/JVI.00556-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00556-18</ArticleId><ArticleId IdType="pmc">PMC6232466</ArticleId><ArticleId IdType="pubmed">30185598</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen J. Waning immunity. Science. 2019;367:224&#x2013;27. doi:10.1126/science.364.6437.224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.364.6437.224</ArticleId><ArticleId IdType="pubmed">31000646</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>